Women with hormone dependent breast cancer experience objective tumor regression in response to initial hormonal therapy but relapses uniformly take place. Second, third and fourth line hormonal therapies frequently cause additional remissions but the mechanisms responsible are poorly understood. As an explanation for these effects, tumors may adapt in response to hormonal therapy and develop """"""""hypersensitivity"""""""" to estrogen through up-regulation of signaling pathways. This results in the development of enhanced responsiveness to the proliferative and pro-apoptotic effects of estradiol. This process of """"""""Adaptive Hypersensitivity"""""""" has important implications for the therapy of women with breast cancer. A working hypothesis states that synergistic interactions among the c-Myc, MAP kinase and mTOR pathways, acting at the level of the cell cycle, result in hypersensitivity to the proliferative effects of estradiol. Type II cellular mechanisms involving death receptor pathways and mitochondria enhance sensitivity to the pro-apoptotic effects of estradiol. This proposal seeks to determine the precise mechanisms mediating hypersensitivity. A major priority is to translate these findings into methods to prevent the development of resistance to hormonal therapy and to enhance the pro-apoptotic effects of estradiol. The ultimate goal is to develop a three pronged treatment approach involving (a) maximum deprivation of estradiol (b) concomitant blockade of signaling pathways to abrogate """"""""adaptive hypersensitivity"""""""" to the proliferative effects of estradiol and (c) cyclic administration of high dose estrogen with enhancers of apoptosis to kill adapted cells. This grant proposal addresses four aims:
Specific Aim 1 : Determine the mechanisms for hypersensitivity to the proliferative effects of estradiol. These studies will utilize induction and reversion strategies to examine the precise roles of the MAP kinase, mTOR and c-Myc pathways in the induction of hypersensitivity and will determine if TSC-1, TSC-2, and Rheb are involved in mTOR up-regulation.
Specific Aim 2 : Determine the mechanisms for hypersensitivity to the pro-apoptotic effects of estradiol and establish that Type II mechanisms take place, which involve death receptor and mitochondrial pathways.
Specific Aim 3 : Enhance estradiol induced apoptosis and utilize pharmacologic agents to prevent hypersensitivity to the proliferative effects of estradiol Three approaches are designed to enhance estradiol induced apoptosis including use of an anti-sense drug directed against Bcl-2, anti-Fas activating antibodies, and the DR3 ligand, TLIA. The mTOR inhibitors FTS, CCI-779, and rapamycin are employed to block growth factor pathways and abrogate hypersensitivity.
Specific Aim 4 : Develop treatment strategies to translate observations about estradiol induced apoptosis into practically applicable clinical therapies. The efficacy of cyclic therapy with sequential use of estradiol deprivation and high dose estrogen administration with enhancers of apoptosis is examined. A clinical trial in women, which is designed to specifically demonstrate that high dose estrogen induces tumor regression through the mechanism of apoptosis will be conducted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084456-08
Application #
7262612
Study Section
Reproductive Endocrinology Study Section (REN)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2000-01-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
8
Fiscal Year
2007
Total Cost
$325,345
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Santen, Richard J; Song, Robert X; Masamura, Shigeru et al. (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19-34
Rahman, Mostafizur; Lax, Sigurd F; Sutter, Carrie H et al. (2008) CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. Drug Metab Dispos 36:963-70
Liu, Gui-Jian; Liu, Giujian; Wu, Yu-Sheen et al. (2008) Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. Breast Cancer Res Treat 111:343-51
Yue, Wei; Wang, Jiping; Li, Yuebai et al. (2005) Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer 117:746-54
Barnes, C J; Vadlamudi, R K; Kumar, R (2004) Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci 61:281-91
Mishra, Sandip K; Mazumdar, Abhijit; Vadlamudi, Ratna K et al. (2003) MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem 278:19209-19
Mazumdar, Abhijit; Kumar, Rakesh (2003) Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 535:6-10
Kumar, Rakesh; Wang, Rui-An; Bagheri-Yarmand, Rozita (2003) Emerging roles of MTA family members in human cancers. Semin Oncol 30:30-7
Vadlamudi, R K; Wang, R A; Mazumdar, A et al. (2001) Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J Biol Chem 276:38272-9
Mazumdar, A; Wang, R A; Mishra, S K et al. (2001) Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3:30-7

Showing the most recent 10 out of 11 publications